The present invention relates to a compound of the general formula (1). wherein A is selected from a group of formula 2. B is selected from a group of formula 3. The compound of formula (1) is suitable for use in a method for treating a disorder relating to the binding of a galectin, such as galectin-3 to a ligand in a mammal, such as a human.